ALMS (Alumis) Total Liabilities: $104.57 Mil (As of Mar. 2026)


ALMS Alumis Inc ALMS
12 GF Score
Price $26.40
! 4 Warning Signs
View Full Analysis

What is Alumis Total Liabilities?

Alumis ALMS +5.52% 12 Total Liabilities is $104.57 Mil as of Mar. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Alumis's Total Liabilities for the quarter that ended in Mar. 2026 was $104.57 Mil.

Alumis's quarterly Total Liabilities increased from Sep. 2025 ($103.24 Mil) to Dec. 2025 ($110.64 Mil) but then declined from Dec. 2025 ($110.64 Mil) to Mar. 2026 ($104.57 Mil).

Alumis's annual Total Liabilities declined from Dec. 2023 ($428.87 Mil) to Dec. 2024 ($80.89 Mil) but then increased from Dec. 2024 ($80.89 Mil) to Dec. 2025 ($110.64 Mil).

Alumis Total Liabilities Historical Data

* Premium members only.

The historical data trend for Alumis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alumis Total Liabilities Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
303.41 428.87 80.89 110.64

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.98 125.60 103.24 110.64 104.57
ALMS
12GF Score
Alumis Inc ALMS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alumis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alumis's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=73.318+(32.244+0.33
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+4.751+0+0)
=110.64

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=411.94-301.297
=110.64

Alumis's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=70.904+(31.222+0.301
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.14+0+0)
=104.57

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=671.588-567.021
=104.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $104.57 Mil mean?
Alumis (ALMS) has a Total Liabilities of $104.57 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alumis and its competitors.
Is Alumis' Total Liabilities too high?
Alumis' current Total Liabilities is $104.57 Mil. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' Total Liabilities compare to SLNO and ARQT?
Alumis' Total Liabilities of $104.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alumis and its competitors. Alumis's current Total Liabilities is $104.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current Total Liabilities of $104.57 Mil. The current Total Liabilities is $104.57 Mil. Alumis' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alumis (ALMS), the current Total Liabilities is $104.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alumis Business Description

Address 280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score

Get the complete analysis for ALMS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.40
Price